重组溶葡萄球菌酶的致突变实验

实验用ICR小鼠经口罐胃染毒（骨髓细胞微核实验和精子畸形实验的剂量分别为2500、5000、10000mg·kg^-1），取其股骨或睾丸组织常规制片，观察分散良好的中期分裂相鼠伤寒沙门氏菌回复突变（Ames）试验采用平板掺入法（剂量分别为0．01、0．04．0．2、1．00、5．00μg·皿^-1），探讨了重组溶葡萄球菌酶的致突变性；预防其遗传危害性和潜在致癌作用的可能性。结果表明：小鼠骨髓、睾丸细胞染色体畸变实验显示：重组溶葡萄球菌酶给药组与阴性对照组比较，差异无显著性（P〉0．05），Ames试验显示各菌株的各测试酞度的回变菌落数均未超过自发回变菌落数的2倍。由此证明在本实验条件下，重组溶葡萄球菌酶无致突变性。

Study on the Mutagenicity of Recombinant Lysostaphin

Objective： To study the mutagenic effect of rlysostaphin and prevent its potential genetic and carcinogenic effect. Methods： ICR mice was gavaged with rlysostaphin （Bone-marrow micronucleus cell test and monstrous sperm test of mices were 2 500, 5 000 and 10 000 mg·kg^-1）. Chromosome sections from femora and testes were prepared with routine method,median-phase chromosome were observed. Amea Salmoonella/microsome plate assay was used. The doses of Ames test were 0.01, 0.04, 0.2, 1.00, 5.00 μg·plate^-1. Result： Chromosome aberration of bone marrow and testes of mice indicated that the rlysostaphin group did not show significant difference from the negative control group （P〉0.05）. Ames test showed that rlysostaphin group didn＇t cause double increase of revertants for all doses in every bacterial stains. Conclusion Rlysostaphin might have no mutagenic effect in this study.